The health system developed the model in collaboration with Aiforia. The model identifies 15 different colorectal cancer tissue samples and uses other parameters to create a recurrence risk score, according to a Jan. 2 Aiforia news release.
“The licensing agreement with the Mayo Clinic enables us to market and sell this AI model for colorectal cancer recurrence risk evaluation globally,” Aiforia CEO Jukka Tapaninen said in the news release. “This is an example of many similar AI model co-development projects which are ongoing with the Mayo Clinic and other partners. These will enable us to significantly enrich our product portfolio.”